iCAN Expands Its Expert Network
iCAN, the premier telehealth company in Cancer has added to its network, Dr. Robert Ozols, an internationally renowned expert in Ovarian Cancer.
Morristown, NJ, November 10, 2015 --(PR.com)-- As part of its mission to help cancer patients and their doctors achieve optimal health care treatment through the innovative use of technology, Cancer Action Now, Inc. (iCAN) is pleased to welcome to our rapidly growing expert team, Robert F. Ozols, MD, PhD. Dr. Ozols is currently an independent cancer consultant and is an internationally renowned expert in Ovarian Cancer. “Dr. Ozols involvement with iCAN is a wonderful addition to the already exceptional faculty in our network and further solidifies iCAN as the premier telehealth company in Cancer,” said CEO of iCAN, Jeff Meehan.
“iCAN serves a tremendous need for those with cancer. When people are diagnosed they are often scared and confused. By making experts like myself immediately available to those seeking information we have an opportunity to quickly get people moving in the right direction improving peoples ability to make decisions on what is right for them and hopefully making the local doctor-patient discussion more efficient,” commented Dr. Ozols.
Dr. Ozols last academic position was at Fox Chase Cancer Center where he served as Senior Vice President Medical Science Division, Medical Director and Professor and from 2010 he served as Chief Clinical Officer, Emeritus. Prior to coming to Fox Chase in 1988, Dr. Ozols was Head of the Experimental Therapeutics Section of the Medicine Branch at the National Cancer Institute. He has developed new clinical approaches to treating women with ovarian cancer and his work in combining carboplatin plus paclitaxel led to this combination becoming the world wide standard regimen for patients with advanced disease.
Dr. Ozols has received numerous awards for his laboratory and clinical work, including: The US Public Health Service Medal of Commendation, The Bristol Myers Squibb Award for Achievement in Cancer Research, The International Gynecologic Cancer Society (IGCS) Award for Excellence in Gynecologic Oncology, and The American Society of Clinical Oncology (ASCO) Distinguished Achievement Award.
Dr. Ozols is the author of numerous publications, books and editorials. He has served on numerous editorial boards of cancer journals and has held senior leadership positions in major scientific and clinical organizations, including: Board of Directors of ASCO and Vice President IGCS. He also served on the Oncology Drug Advisory Committee (ODAC) to the FDA. He was a Principle Investigator for the Gynecologic Oncology Group (GOG) for two decades and served on numerous advisory positions for the NCI, cancer centers, and cancer research organizations.
Please call 844-GET-iCAN (438-4226) or email manderson@canceractionnow.com for more information about iCAN or visit our website at http://www.canceractionnow.com.
About Cancer Action Now, Inc.
The mission of iCAN is to help cancer patients and their doctors achieve optimal health care treatment by providing fast, customized information about their cancer management from top cancer experts. iCAN’s carefully chosen network of cancer experts offers collective expertise with a common goal of improving cancer outcomes by facilitating the use of technology and enabling immediate communication of up-to-date clinical information. This empowers physicians and patients to more rapidly make decisions and initiate optimal treatment earlier, regardless of location. iCAN, through a proprietary, HIPAA compliant and secure platform, connects providers, patients and caregivers with many of the top cancer experts in the US who are prepared to evaluate a wide range of cancer cases. iCAN experts intend to ease concerns, answer questions and provide clear information. Please visit www.canceractionnow.com or connect with iCAN on Facebook, Twitter, LinkedIn and Pinterest.
“iCAN serves a tremendous need for those with cancer. When people are diagnosed they are often scared and confused. By making experts like myself immediately available to those seeking information we have an opportunity to quickly get people moving in the right direction improving peoples ability to make decisions on what is right for them and hopefully making the local doctor-patient discussion more efficient,” commented Dr. Ozols.
Dr. Ozols last academic position was at Fox Chase Cancer Center where he served as Senior Vice President Medical Science Division, Medical Director and Professor and from 2010 he served as Chief Clinical Officer, Emeritus. Prior to coming to Fox Chase in 1988, Dr. Ozols was Head of the Experimental Therapeutics Section of the Medicine Branch at the National Cancer Institute. He has developed new clinical approaches to treating women with ovarian cancer and his work in combining carboplatin plus paclitaxel led to this combination becoming the world wide standard regimen for patients with advanced disease.
Dr. Ozols has received numerous awards for his laboratory and clinical work, including: The US Public Health Service Medal of Commendation, The Bristol Myers Squibb Award for Achievement in Cancer Research, The International Gynecologic Cancer Society (IGCS) Award for Excellence in Gynecologic Oncology, and The American Society of Clinical Oncology (ASCO) Distinguished Achievement Award.
Dr. Ozols is the author of numerous publications, books and editorials. He has served on numerous editorial boards of cancer journals and has held senior leadership positions in major scientific and clinical organizations, including: Board of Directors of ASCO and Vice President IGCS. He also served on the Oncology Drug Advisory Committee (ODAC) to the FDA. He was a Principle Investigator for the Gynecologic Oncology Group (GOG) for two decades and served on numerous advisory positions for the NCI, cancer centers, and cancer research organizations.
Please call 844-GET-iCAN (438-4226) or email manderson@canceractionnow.com for more information about iCAN or visit our website at http://www.canceractionnow.com.
About Cancer Action Now, Inc.
The mission of iCAN is to help cancer patients and their doctors achieve optimal health care treatment by providing fast, customized information about their cancer management from top cancer experts. iCAN’s carefully chosen network of cancer experts offers collective expertise with a common goal of improving cancer outcomes by facilitating the use of technology and enabling immediate communication of up-to-date clinical information. This empowers physicians and patients to more rapidly make decisions and initiate optimal treatment earlier, regardless of location. iCAN, through a proprietary, HIPAA compliant and secure platform, connects providers, patients and caregivers with many of the top cancer experts in the US who are prepared to evaluate a wide range of cancer cases. iCAN experts intend to ease concerns, answer questions and provide clear information. Please visit www.canceractionnow.com or connect with iCAN on Facebook, Twitter, LinkedIn and Pinterest.
Contact
Maud Anderson
1-844-438-4226
1-844-438-4226
Contact
Categories